MacroGenics (MGNX)
(Delayed Data from NSDQ)
$14.56 USD
+0.19 (1.32%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.54 -0.02 (-0.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
MGNX 14.56 +0.19(1.32%)
Will MGNX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MGNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MGNX
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
MGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates
MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?
MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why
Other News for MGNX
Snap upgraded, Apple downgraded: Wall Street's top analyst calls
B. Riley starts MacroGenics at Buy on 'de-risked' lead asset
MacroGenics initiated with bullish view at B. Riley
Buy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial Results
Notable Thursday Option Activity: MGNX, TGT, IP